- PTACH
-
- $42.00
-
2026-07-27
- CAS:848354-66-5
- Purity: 98.75%
- Supply Ability: 10g
|
| Product Name: | PTACH | | Synonyms: | Cpd 51, S-[6-(4-Phenyl-2-thiazolylcarbamoyl)hexyl] thioisobutyrate;2-MethylpropanethioicacidS-[7-oxo-7-[(4-phenyl-2-thiazolyl)amino]heptyl]ester;NCH 51;S-(7-Oxo-7-((4-phenylthiazol-2-yl)amino)-heptyl) 2-methylpropanethioate;PTACH (NCH-51);HDAC Inhibitor XXII, NCH51;Propanethioic acid,2-methyl-, S-[7-oxo-7-[(4-phenyl-2-thiazolyl)amino]heptyl] ester;NCH51, >98% | | CAS: | 848354-66-5 | | MF: | C20H26N2O2S2 | | MW: | 390.56 | | EINECS: | | | Product Categories: | | | Mol File: | 848354-66-5.mol |  |
| | PTACH Chemical Properties |
| Melting point | 127-128 °C(Solv: hexane (110-54-3); ethyl acetate (141-78-6)) | | density | 1.181±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: soluble26mg/mL | | form | White powder | | pka | 9.52±0.50(Predicted) | | color | White to off-white | | InChI | 1S/C20H26N2O2S2/c1-15(2)19(24)25-13-9-4-3-8-12-18(23)22-20-21-17(14-26-20)16-10-6-5-7-11-16/h5-7,10-11,14-15H,3-4,8-9,12-13H2,1-2H3,(H,21,22,23) | | InChIKey | MDYDGUOQFUQOGE-UHFFFAOYSA-N | | SMILES | CC(C)C(=O)SCCCCCCC(=O)Nc1nc(cs1)-c2ccccc2 |
| Hazard Codes | Xi | | Risk Statements | 41 | | Safety Statements | 26-39 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | PTACH Usage And Synthesis |
| Uses | NCH 51 is a Histone deacetylase inhibitor. | | Definition | ChEBI: 2-methylpropanethioic acid S-[7-oxo-7-[(4-phenyl-2-thiazolyl)amino]heptyl] ester is an aromatic amide. | | General Description | A cell-permeable S-isobutyryl prodrug that is processed intracellularly to form the potent HDAC inhibitor NCH-31 (IC50 = 48 and 170 nM, respectively, using partially purified HDAC1 or HeLa nuclear extract) that is predicted to exhibit a similar HADC binding mode as that of SAHA with its sulfhydryl replacing SAHA′s hydroxamate as the active-site zinc-targeting group. NCH-51 is shown to exhibit comparable antiproliferative (mean IC50 = 3.8 μM vs. 3.7 μM for SAHA; 48 h treatment) and apoptotic activity as SAHA against various cancer cell lines, but not PBMCs from 4 healthy individuals (IC50 >30 μM with either drug), and the antioxidant N-Acetyl-L-Cysteine (NAC; Cat. No. 106425) at 2 mM is reported to abolish the cell-growth inhibition caused by either 3 μM NCH-51 or SAHA in the Multiple Myeloma U266 cultures. Half-life in human plasma at 37 °C = 24 h. | | Biological Activity | Histone deacetylase (HDAC) inhibitor. Inhibits growth of various cancer cells in vitro (EC 50 = 1.1-9.1 μ M). | | Biochem/physiol Actions | HDAC inhibitor; more potent than the majority of HDAC inhibitors except for SAHA (gold standard). | | references | [1]. suzuki t, hisakawa s, itoh y, et al. identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor. bioorg med chem lett, 2007, 17(6): 1558-1561.
[2]. suzuki t, nagano y, kouketsu a, et al. novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of saha-based non-hydroxamates. j med chem, 2005, 48(4): 1019-1032.
[3]. sanda t, okamoto t, uchida y, et al. proteome analyses of the growth inhibitory effects of nch-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. leukemia, 2007, 21(11): 2344-2353.
[4]. victoriano af, imai k, togami h, et al. novel histone deacetylase inhibitor nch-51 activates latent hiv-1 gene expression. febs lett, 2011, 585(7): 1103-1111. |
| | PTACH Preparation Products And Raw materials |
|